Preeclampsia (PE) Screening Test
- TOP
- Examination and price list
- Preeclampsia (PE) Screening Test
Preeclampsia (PE) screening test
This test is conducted to identify pregnant women at high risk in the first trimester and to propose appropriate self-management and preventive measures.
We measure maternal serum PlGF (placental growth factor), mean arterial pressure (MAP)—the average of two measurements in each arm—and the uterine artery Doppler pulsatility index (UtA-PI). For each measurement, the MoM (multiple of the median) is calculated, and the individual risk of preeclampsia (PE) is assessed.
MoM indicates how far a value deviates from 1.00, the median in uncomplicated pregnancies. The PE risk is then calculated by combining these MoMs with maternal characteristics (age, weight, height, medical/obstetric history, etc.).
Patients between 11 weeks 0 days and 13 weeks 6 days of gestation are eligible. Therefore, this test is provided to all patients undergoing our First-Trimester Fetal Screening (¥49,800, tax included).
CRIFM is the first in Japan to implement PE screening test as a routine test for all patients in the first trimester.
Fees for the Preeclampsia (PE) Screening Test
This screening is included in the First-Trimester Fetal Screening.
The PE screening test cannot be performed as a stand-alone service.
| First-Trimester Fetal Screening (per fetus) *Includes the PE screening test |
49,800 yen (tax included) |
|---|
What is Preeclampsia (PE)?
Preeclampsia is a serious pregnancy complication characterized by maternal hypertension and proteinuria. If left untreated, it increases the risk of multiple organ dysfunction, fetal growth restriction, preterm birth, and can be life-threatening for both mothers and babies.
International research has reported that starting low-dose aspirin by 16 weeks of gestation significantly reduces the incidence of preeclampsia (see Ref.). For this reason, many countries conduct first-trimester screening.
PE risk is often missed in routine prenatal checkups, and most pregnant patients have few subjective symptoms. Obtaining an objective assessment of PE risk in early pregnancy helps protect the lives of both mother and baby.
By standardly adding this test to the First-Trimester Screening, we provide a comprehensive assessment for all pregnant patients to support a safer, more reassuring pregnancy. For those identified as high risk, we coordinate follow-up with the patient’s obstetrician.
Please feel free to contact us.
Learn more about the First-Trimester Fetal Screening here
【Reference Sites and Bibliography】
1. Nguyen-Hoang L, Dinh LT, Tai AST, Nguyen DA, Pooh RK, et al. Implementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia. Circulation. (IF = 35.5) 2024 Oct 15;150(16):1223-1235.
2. Pooh RK First-trimester preterm preeclampsia prediction model for prevention with low-dose aspirin.
J Obstet Gynaecol Res. Official Research Journal of the Japan Society of Obstetrics and Gynecology. (IF = 1.6) 2024 May ; 50(5):793-799.
3. Chaemsaithong P, Pooh RK, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population.
Am J Obstet Gynecol. (IF = 8.5) 2019 Dec;221(6):650.e1-650.e16.
4. Rolnik DL, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. (IF = 96.2) 2017 Aug 17;377(7):613-622.